Skip to main navigation
Skip to search
Skip to main content
The Ohio State University Home
Search content at The Ohio State University
Home
Profiles
Research units
Research output
Projects
Consolidation Therapy in Acute Myeloid Leukemia
Gregory K. Behbehani
, Bruno C. Medeiros
Comprehensive Cancer Center
Comprehensive Cancer Center - Innate Immunity
Internal Medicine
Internal Medicine - Hematology
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Consolidation Therapy in Acute Myeloid Leukemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Myeloid Leukemia
100%
Consolidation Therapy
100%
Complete Remission
75%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
75%
Post-remission Therapy
50%
Risk Disease
50%
Clinical Trials
25%
Leukemia Patients
25%
Elderly Patients
25%
Cytarabine
25%
Relapse Rate
25%
Cytotoxic Chemotherapy
25%
Clinical High Risk
25%
Salvage Therapy
25%
High-dose Cytarabine
25%
Young Patients
25%
No Significant Difference
25%
Median Time
25%
Induction Regimen
25%
Multiagent Chemotherapy
25%
Post-remission
25%
Favorable Risk
25%
Consolidation Chemotherapy
25%
Post-remission Chemotherapy
25%
Risk Management Strategies
25%
Evidence-based Support
25%
Adverse Risk
25%
Core Binding Factor Leukemias
25%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Cytarabine
40%
Autologous Hematopoietic Stem Cell Transplantation
40%
Diseases
40%
Clinical Trial
20%
Drug Megadose
20%
Cytotoxic Chemotherapy
20%
Elderly Patient
20%
Recurrence Risk
20%
Chemotherapy Agent
20%
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Salvage Therapy
20%
Consolidation Chemotherapy
20%
Core Binding Factor
20%
Chemotherapy
20%